Created at	Source	Raw Value	Validated value
Oct. 31, 2020, 11:31 p.m.	usa	To evaluate safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins ("S" and "M").;To evaluate the efficacy and safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins ("S" and "M").	To evaluate safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins ("S" and "M").;To evaluate the efficacy and safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins ("S" and "M").